马拉维生命科学
关于 Maravai LifeSciences
Maravai Lifesciences Holdings, engages in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm’s brands include TriLink BioTechnologies, Cygnus, Glen Research, and Alphazyme. It operates through the TriLink and Cygnus segments. The TriLink segment manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Cygnus segment sells biologic safety testing products and highly specialized analytical products for use in biologic manufacturing process development, including custom product-specific antibody and assay development services. It also operates through the following geographical segments: North America, Asia Pacific, Europe, the Middle East, and Africa, and Latin and Central America. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and为一家企业，主要从事相关业务。 2014年成立。总部位于San Diego, CA。
- 成立时间
- 2014
- 首席执行官
- Mr. Bernd Brust
- 员工人数
- 435
- 总部地址
- San Diego, California, United States of America
- 财年结束日
- 12-31
- 官方网站
- maravai.com
公司概况
- 交易所
- US
- 股票代码
- MRVI
- 市值排名
- #3116
- 上市日期
- 2020-11-20
- 市值
- 1.01B
- 流通市值
- 696.68M
- 总股数
- 148.99M
- 流通股数
- 102.60M
行业与主题板块
报价时间 2026-10-16 20:02:27 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
马拉维生命科学 讨论区 0 条评论